A comprehensive analysis of GLP-1 market strategy and performance across the 4Ps of marketing.
Candidate | Benefit |
---|---|
Eli Lilly’s Orforglipron | Oral formulation |
Viking Therapeutics’ VK-2735 | Significant weight loss |
Altimmune's Pemvidutide | Improvements in blood pressure |
Zealand Pharma's Petrelintide | Reduces appetite |
B. Ingelheim's Survodutide | Improves glycemic control |
Sciwind's ecnoglutide | Longer duration of action |
Takeda's cetilistat | Reduces the absorption of fat |